GATA3 and cancer: EZH2 inhibition differentiates EZH2 high basal cells to a luminal-like phenotype by derepressing GATA3 and renders them sensitive to endocrine therapy.20 Polycomb inhibitors, especially those directed against the PRC2 catalytic subunit EZH2 have shown responses in preclinical studies of cancer therapy.9